Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Actionability of Molecular Targets in Multi-Ethnic Breast Cancer Patients: A Retrospective Single-Institutional Study.

Molecular diagnosis & therapy - 1 May 2025

Kang Irene, Naghi Leah, Yost Susan E, Mortimer Joanne

Abstract excerpt

BACKGROUND: Precision oncology is making remarkable advancements in optimizing patient care by personalizing treatments. To date, the US Food and Drug Administration (FDA) has approved poly(ADP-ribose) polymerase inhibitors (PARPi) olaparib (Lynparza, AstraZeneca and Merck) and talazoparib (Talzenna, Pfizer Oncology Together™) for germline or somatic BRCA1/2-mutated metastatic breast cancer (BC) patients, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ethnicity

Share to ARID1A gene

Share to GEM gene

Share to Molecular Targeted Therapy

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 40192953
DOI: 10.1007/s40291-025-00777-7
PMCID: PMC12062054

Genes

PIK3CA
BRCA1
AKT1
ESR1
PTEN
BRCA2
PALB2
GEM
ARID1A
ATM
CCND1
CDH1
CDKN2A
CHEK2
ERBB2
FGF19
FGF3
FGF4
FGFR1
GATA3
MAP3K1
MCL1
MYC
NF1
RB1
TP53
ZNF703

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Actionability of Molecular Targets in Multi-Ethnic Breast Cancer Patients: A Retrospective Single-Institutional Study.PMID 40192953Read ↗

Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.Semantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients.Semantic proximity Read ↗

Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer.Semantic proximity Read ↗

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerSemantic proximity Read ↗

Tumor Mutational Landscape and Its Correlation with Histopathological Characteristics in Breast CancerSemantic proximity Read ↗

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testingSemantic proximity Read ↗

Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.Semantic proximity Read ↗

Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid TumorsSemantic proximity Read ↗

Breast cancer disparities in outcomes; unmasking biological determinants associated with racial and genetic diversity.Semantic proximity Read ↗

From Static to Dynamic: Adaptive Molecular Subtyping in Treated Breast Cancers—Evidence from Single‐Center Retrospective Cohort StudySemantic proximity Read ↗

Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.